

Mr. Iñigo de la Lastra

Head of Secondary Markets
CNMV
Edison, 4
28006 Madrid

Barcelona (Spain), March 12, 2015

RELEVANT FACT

Dear Sir,

In accordance with Law 24/1988, 28th July, relative to the regulation of the stock market and related provisions, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), formerly NATRACEUTICAL SA ("Natraceutical"), informs that on **Monday March 23, at 11:00 am CET**, it will make a presentation of the company and 2014 proforma results, following the recent merger between Reig Jofre and Natraceutical.

The presentation will be webcasted live, in English only, and it will be hosted by:

- Ignasi Biosca, CEO
- Gabriel Roig, CFO
- Gloria Folch, IR

Given the recent merger between Reig Jofre and Natraceutical and, therefore, the lack of updated analyst research on the resulting company, a factsheet is attached hereafter, which includes connection details to this presentation.

Yours faithfully,

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre SA

A new company following the merger with Natraceutical

Since December 31, 2014, Reig Jofre is the result of the merger between the Spanish listed company Natraceutical SA and the family-owned pharmaceutical company Laboratorio Reig Jofre SA.

Following the merger, Natraceutical SA changed its name to Laboratorio Reig Jofre SA and it trades now under the ticker RJF (former NTC).

The new Reig Jofre is the fifth largest Spanish pharmaceutical company by turnover listed on the Spanish stock market.

Reig Jofre specializes in the research, development, manufacture and marketing of medicines and nutritional supplements, as well as in specialized contract manufacturing. The company directs its R&D to develop new pharmaceutical products either internally or in partnership with bio-ventures and research centers, as well as variations in the formulation of known active principles in order to modify their release, improve their dosage and to obtain new routes of administration or indications. It also develops and manufactures injectable generics for licensing. Reig Jofre has an outstanding experience in the development and manufacture of lyophilized injectables, beta lactam antibiotics, topical dermatological products and nutraceuticals.

Prior to the merger, Natraceutical's figures in 2013 stood at: 31.4 M€ turnover; 2.6 M€ EBITDA and 2.1 M€ profit before taxes. After the merger, the new company stands at 152.5 M€ turnover; 15.0 M€ EBITDA and 9.2 M€ profit before taxes.

Headquartered in Barcelona (Spain), the new Reig Jofre has strengthened its market position by diversifying its product portfolio in the segments of pharma (69% of combined sales in 2013), OTC (16%) and food supplements (15%), as well as its international presence, whose sales outside Spain represent 64% of the joint turnover and are distributed between France (17%), Germany (10%), UK (9%), Sweden (6%) and about fifty other countries on the five continents (21%).

CEO: Ignasi Biosca / CFO: Gabriel Roig / IR: Gloria Folch

Keep informed of the latest news about Reig Jofre by subscribing to <http://www.reigjofre.com/en/subscription-center>

Av. de les Flors
08970 Sant Joan Despí
Barcelona, Spain
T. +34 93 480 67 10

www.reigjofre.com

FIRST LIFE WEBCAST

Topic: Merger and 2014 results

Date: March 23, 2015

Time: 11:00 am CET

Language: English only

Hosted by: CEO, CFO and IR

Link: <http://goo.gl/ewCAF7>

Questions may also be sent prior to March 23, to investors@reigjofre.com

Bloomberg / Reuters: RJF SM / RJFE.MC

Outstanding shares: 1,264,284,408

Share price*: 0.299 €

Market cap: 378 M€

Free float: 13%

* March 4, 2015

	2012	2013	2014	CAGR 12-14
Sales	135.1	152.9	152.5	6.2%
Gross margin	81.1	93.4	97.2	9.5%
% sales	60%	61%	64%	
EBITDA	11.5	18.2	15.0	14.2%
% sales	9%	12%	10%	
EBIT	6.3	13.4	10.0	26.0%
% sales	5%	9%	7%	
EBT	2.7	12.0	9.2	84.6%
% sales	2%	8%	6%	
Net profit	2.9	8.6	6.9	54.3%

Non-audited proforma figures. In million euros

	2014
NFD/EBITDA	0.99 x
NFD/Equity	3.9%
NFD/BV	12.6%
EBITDA/Fin. int.	16.2 x
EV/Sales	2.6 x
EV/EBITDA	26.2 x
EV/EBIT	42.7 x
PER	54.8 x
P/FCF	35.1 x
P/BV	3.2 x
EPS	0.005€
BVPS	0.093€
DPS	-
FCF yield	2.9%
ROCE	7.5%